Contineum (NASDAQ: CTNM) CMO sells 10,833 shares after option exercise
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Contineum Therapeutics, Inc. executive Tim Watkins, CMO & Head of Development, reported an exercise-and-sell transaction in Class A Common Stock. On June 30, 2026, he exercised stock options to acquire 10,833 shares at an exercise price of $4.50 per share and sold 10,833 shares in open-market trades at a weighted average price of $16.0242 per share, with individual sale prices ranging from $16.00 to $16.15. The sale was carried out under a Rule 10b5-1 trading plan adopted on September 23, 2025. Following these transactions, he directly holds 19,794 shares of Class A Common Stock, which includes 8,961 shares acquired through the company’s Employee Stock Purchase Plan, and retains 238,334 stock options with a $4.50 exercise price expiring on April 27, 2035, subject to continued vesting.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 10,833 shares ($173,590)
Net Sell
3 txns
Insider
Watkins Tim
Role
CMO & Head of Development
Sold
10,833 shs ($174K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 10,833 | $0.00 | -- |
| Exercise | Class A Common Stock | 10,833 | $4.50 | $49K |
| Sale | Class A Common Stock | 10,833 | $16.0242 | $174K |
Holdings After Transaction:
Stock Option (right to buy) — 238,334 shares (Direct, null);
Class A Common Stock — 19,794 shares (Direct, null)
Footnotes (1)
- These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Includes 8,961 shares of the Issuer's Class A Common Stock acquired by the Reporting Person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service.
Key Figures
Shares sold: 10,833 shares
Weighted average sale price: $16.0242 per share
Option exercise price: $4.50 per share
+3 more
6 metrics
Shares sold
10,833 shares
Class A Common Stock sold on June 30, 2026
Weighted average sale price
$16.0242 per share
Open-market sales, prices from $16.00 to $16.15
Option exercise price
$4.50 per share
Stock option to buy Class A Common Stock
Shares held after transaction
19,794 shares
Direct Class A Common Stock ownership following transactions
Options remaining
238,334 options
Stock options with $4.50 exercise price expiring April 27, 2035
ESPP shares included
8,961 shares
Class A Common Stock acquired via Employee Stock Purchase Plan
Key Terms
Rule 10b5-1 trading plan, Employee Stock Purchase Plan, weighted average price, Stock Option (right to buy), +1 more
5 terms
Rule 10b5-1 trading plan financial
"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Purchase Plan financial
"Includes 8,961 shares of the Issuer's Class A Common Stock acquired ... pursuant to its Employee Stock Purchase Plan."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)" for derivative transaction"
vesting financial
"One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Contineum Therapeutics (CTNM) executive Tim Watkins report in this Form 4?
Tim Watkins reported an option exercise and matching sale of shares. He exercised options for 10,833 Class A shares at $4.50 and sold 10,833 shares in open-market trades at a weighted average price of $16.0242 on June 30, 2026.
What options did Tim Watkins exercise in Contineum Therapeutics (CTNM)?
He exercised stock options covering 10,833 shares of Class A Common Stock at an exercise price of $4.50 per share. These options are part of a larger grant with a remaining 238,334 option shares expiring on April 27, 2035, subject to vesting.
What is the vesting schedule of the Contineum Therapeutics (CTNM) stock options held by Tim Watkins?
The filing notes that one-half of the relevant option grant vested on October 28, 2025. The remaining half vests in 36 equal monthly installments thereafter, contingent on Tim Watkins’ continuous service with the company during the vesting period.